Literature DB >> 19255488

Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex.

Yohei Mukai1, Teruya Nakamura, Yasuo Yoshioka, Shin-ichi Tsunoda, Haruhiko Kamada, Shinsaku Nakagawa, Yuriko Yamagata, Yasuo Tsutsumi.   

Abstract

Tumour necrosis factor receptor type 2 (TNFR2, TNFRSF1B) is an essential receptor for various host-defence functions of tumour necrosis factor alpha (TNF). As part of studies to determine the structure of TNFR2, the formation, crystallization and preliminary X-ray diffraction analysis of the TNF-TNFR2 complex are described. The TNF-TNFR2 complex, which comprises one TNF trimer and three TNFR2 monomers, was confirmed and purified by size-exclusion chromatography. Crystals of the TNF-TNFR2 complex were obtained using polyethylene glycol 3350 as a precipitant. The crystal belonged to space group P2(1)2(1)2(1), with unit-cell parameters a = 74.5, b = 117.4, c = 246.8 A. Assuming the presence of two TNF-TNFR2 complexes in the asymmetric unit, the Matthews coefficient V(M) was 2.49 A(3) Da(-1) and the solvent content of the crystal was 50.7%. The crystal diffracted to 2.95 A resolution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255488      PMCID: PMC2650442          DOI: 10.1107/S1744309109004461

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  21 in total

1.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.

Authors:  M J Eck; S R Sprang
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

2.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

Authors:  Marc Feldmann; Ravinder N Maini
Journal:  Nat Med       Date:  2003-10       Impact factor: 53.440

Review 3.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

4.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

Review 5.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

6.  Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.

Authors:  Yohei Mukai; Hiroko Shibata; Teruya Nakamura; Yasuo Yoshioka; Yasuhiro Abe; Tetsuya Nomura; Madoka Taniai; Tsunetaka Ohta; Shinji Ikemizu; Shinsaku Nakagawa; Shin-ichi Tsunoda; Haruhiko Kamada; Yuriko Yamagata; Yasuo Tsutsumi
Journal:  J Mol Biol       Date:  2008-12-06       Impact factor: 5.469

7.  The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection.

Authors:  Michel I Kafrouni; Geri R Brown; Dwain L Thiele
Journal:  J Leukoc Biol       Date:  2003-07-15       Impact factor: 4.962

8.  Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation.

Authors:  D W Banner; A D'Arcy; W Janes; R Gentz; H J Schoenfeld; C Broger; H Loetscher; W Lesslauer
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release.

Authors:  M Leist; F Gantner; S Jilg; A Wendel
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

10.  A graphical user interface to the CCP4 program suite.

Authors:  Elizabeth Potterton; Peter Briggs; Maria Turkenburg; Eleanor Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2003-06-27
View more
  3 in total

Review 1.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

Review 2.  Development of novel drug delivery systems using phage display technology for clinical application of protein drugs.

Authors:  Kazuya Nagano; Yasuo Tsutsumi
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2016       Impact factor: 3.493

3.  Triptolide attenuates inhibition of ankylosing spondylitis-derived mesenchymal stem cells on the osteoclastogenesis through modulating exosomal transfer of circ-0110634.

Authors:  Wei Ji; Yueyang Lu; Zhuoyi Ma; Ke Gan; Yan Liu; Yue Cheng; Junliang Xu; Shijia Liu; Yunke Guo; Shanhang Han; Zengyan Zhao; Hanmei Xu; Weiyan Qi
Journal:  J Orthop Translat       Date:  2022-09-16       Impact factor: 4.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.